Orforglipron vs Semaglutide
A side-by-side research comparison of Orforglipron and Semaglutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Orforglipron | Semaglutide |
|---|---|---|
| Full name | Orforglipron (Oral Non-Peptide GLP-1 Agonist) | Semaglutide (GLP-1 Receptor Agonist) |
| Category | Weight Management | Weight Management |
| Status | Phase 3 Clinical Trial | FDA Approved |
| Mechanism | Small molecule agonist of GLP-1 receptors that mimics native GLP-1 binding without requiring peptide structure. Achieves full receptor activation with standard oral bioavailability. | Binds GLP-1 receptors in the pancreas to stimulate insulin secretion, in the brain to reduce appetite, and in the GI tract to slow gastric emptying. 94% homology to native GLP-1. |
| Molecular weight | ~550 Da | 4,114 Da |
| Half-life | 25-60 hours | 7 days (168 hours) |
| Bioavailability | Moderate-High (oral) | High (SubQ ~89%), Moderate (oral ~1% with SNAC) |
| Typical dose | 12-45 mg | 0.25 mg → titrate up to 2.4 mg |
| Frequency | Once daily | Once weekly |
| Route | Oral | Subcutaneous injection |
Orforglipron reported benefits
- Oral administration (no injection)
- No fasting requirement
- Significant weight loss (8-14%)
- Small molecule stability
- Lower manufacturing cost potential
Semaglutide reported benefits
- Significant weight loss (15-17%)
- Improved glycemic control
- Cardiovascular risk reduction
- Reduced food cravings
- Lower HbA1c
Related comparisons
Research and educational reference only. Not medical advice.